The obesity treatment market in India is on the brink of transformation with the anticipated arrival of several oral GLP-1 weight-loss pills, including those from Chinese biotech companies such as Hengrui and Huadong. Industry experts and endocrinologists predict that the launch of these oral medications will lead to greater adoption compared to injectable options. The oral GLP-1 pills, like Eli Lilly's Orforglipron and Novo Nordisk's semaglutide, are expected to be more convenient and cost-effective, making them accessible to a broader patient base. Rajiv Kovil, a diabetologist in Mumbai, notes that these pills do not require cold storage and are easier to administer, which is crucial for many patients in India. The expected weight loss efficacy of these oral medications ranges from 10-16%, which could significantly benefit those who are needle-phobic. Eli Lilly is set to introduce Orforglipron in India by the end of the year, adding to its portfolio of weight-loss innovations. Novo's oral semaglutide, Rybelsus, launched in India in 2022, has already generated sales of ₹500 crore (approximately $60 million USD).